The Venture Codex Logo

The Venture Codex

Northumbria University

Sutherland Building, Northumberland Road, Newcastle upon Tyne, Tyne and Wear, NE1 8ST, United Kingdom

Overview

We are one of the largest and most successful universities in the UK with approximately 36,000 students studying programmes at home and overseas. The University has a strong reputation for the quality of its teaching and research activities and offers provision in 29 of the 32 most popular academic disciplines. We are the largest UK provider of education in Hong Kong, with strong links in Malaysia, Singapore and the Caribbean, as well as having a small base in London. Northumbria is one of the top ten universities in the UK, the fourth largest for international students and the largest in the North East for the number of taught postgraduate students. Our City Centre campus has benefited from a £160m investment in recent years. The award-winning City Campus East is home to Law, Design and Business students. City Campus West was completed in 2010 with the opening of the new Students’ Union building and Sport Central. In the last four years, 200 graduates have been helped to start-up their own companies. More than 600 businesses sponsor Northumbria programmes and many students graduate with professional accreditation. The University has the highest number of employed graduates in the North East. Research and enterprise is a major priority, with more than 1,000 worldwide clients and a significant number of commercial and professional collaborations and partnerships.

Total investments
1
Lead investments
0
Investments · 12mo
0
Active investors
5

Sector focus

  • Education
  • Higher Education
  • Universities
Visit website

Investment portfolio

  • PulmoBiomed

    Participated · Equity · Feb 2024

    PulmoBioMed is a Newcastle Upon Tyne–based company that provides breath sampling technology offering a non-invasive way to obtain uncontaminated deep lung fluid samples. Its hand-held PBM-HALE device captures exhaled breath, separates large mouth-origin aerosol droplets from fine deep-lung droplets, and collects samples in about two minutes. Clinical studies showed it provided uncontaminated deep lung samples and helped detect and quantify lung infections and inflammation in 100% of symptomatic cases. The company was founded during the pandemic to address slow diagnosis of respiratory diseases and is led by CEO and Founder Sterghios Moschos. PulmoBioMed intends to use new funding to develop a manufacturing process to scale production, register the product in the US, and relocate from the university to new city-centre premises. It also secured a £700K Innovate UK grant and plans to create seven new jobs in the year ahead.

Team

  • John Hunter Rutherford

    Founder

  • Honglei Li

    Senior Lecturer

    LinkedIn
  • Hamdi Torun

    Associate Professor

    LinkedIn
  • Graham Hillier

    Royal Society Entrepreneur in Residence

    LinkedIn